





































Transplantation DIRECT         2021 www.transplantationdirect.com 1
Long-term, Prolonged-release Tacrolimus-based 
Immunosuppression in De Novo Liver Transplant 
Recipients: 5-year Prospective Follow-up of 
Patients in the DIAMOND Study
Styrbjörn Friman, MD, PhD,1 Giuseppe Tisone, MD,2 Frederik Nevens, MD, PhD,3 Frank Lehner, MD,4  
Walter Santaniello, MD,5 Wolf O. Bechstein, MD, PhD,6 Sergey V. Zhuvarel, MD,7 Helena Isoniemi, MD, PhD,8  
Oleg O. Rummo, MD,9 Jürgen Klempnauer, MD,4 Swapneel Anaokar, MBBS, MD,10 Martin Hurst, MBBS, FRCP,10  
Gbenga Kazeem, PhD,10,11 Nasrullah Undre, PhD,10 and Pavel Trunečka, MD, PhD12
Received 7 October 2020. Revision received 8 March 2021.
Accepted 9 March 2021.
1 Transplant Institute, Sahlgrenska University Hospital and Sahlgrenska 
Academy, University of Gothenburg, Gothenburg, Sweden.
2 Department of Surgical Sciences, University of Rome “Tor Vergata,” Rome, Italy.
3 Department of Hepatology, University Hospitals KU Leuven, Leuven, Belgium.
4 Department of General, Visceral, and Transplantation Surgery, Hannover 
Medical School, Hannover, Germany.
5 Unit of Hepatobiliary Surgery and Liver Transplant Center, Department of 
Gastroenterology and Transplantation, “A. Cardarelli” Hospital, Naples, Italy.
6 Department of Surgery, Goethe University Hospital and Clinics, Frankfurt, 
Germany.
7 N.V. Sklifosovsky Research Institute, Moscow, Russian Federation.
8 Department of Transplantation and Liver Surgery Clinic, Helsinki University 
Hospital, Helsinki, Finland.
9 Republican Scientific and Practical Center for Organ and Tissue Transplantation, 
Minsk, Belarus.
10 Astellas Pharma Europe, Chertsey, United Kingdom.
11 BENKAZ Consulting Ltd, Cambridge, United Kingdom.
12 Transplant Center, Institute for Clinical and Experimental Medicine, Prague, 
Czech Republic.
Liver Transplantation
Background. Immunosuppression with calcineurin inhibitors (CNIs) is reportedly associated with risk of renal impairment 
in liver transplant recipients. It is believed that this can be mitigated by decreasing initial exposure to CNIs or delaying CNI 
introduction until 3–4 d posttransplantation. The ADVAGRAF studied in combination with mycophenolate mofetil and basi-
liximab in liver transplantation (DIAMOND) trial evaluated different administration strategies for prolonged-release tacrolimus 
(PR-T). Methods. DIAMOND was a 24-wk, open-label, phase 3b trial in de novo liver transplant recipients randomized 
to: PR-T 0.2 mg/kg/d (Arm 1); PR-T 0.15–0.175 mg/kg/d plus basiliximab (Arm 2); or PR-T 0.2 mg/kg/d delayed until day 
5 posttransplant plus basiliximab (Arm 3). In a 5-y follow-up, patients were maintained on an immunosuppressive regimen 
according to standard clinical practice (NCT02057484). Primary endpoint: graft survival (Kaplan-Meier analysis). Results. 
Follow-up study included 856 patients. Overall graft survival was 84.6% and 73.5% at 1 and 5 y post transplant, respectively. 
Five-year rates for Arms 1, 2, and 3 were 74.7%, 71.5%, and 74.5%, respectively. At 5 y, death-censored graft survival in the 
entire cohort was 74.7%. Overall graft survival in patients remaining on PR-T for ≥30 d was 79.1%. Graft survival in patients 
who remained on PR-T at 5 y was 87.3%. Patient survival was 86.6% at 1 y and 76.3% at 5 y, with survival rates similar in the 
3 treatment arms at 5 y. Estimated glomerular filtration rate at the end of the 24-wk initial study and 5 y posttransplant was 
62.1 and 61.5 mL/min/1.73 m2, respectively, and was similar between the 3 treatment arms at 5 y. Overall, 18 (2.9%) patients 
had ≥1 adverse drug reaction, considered possibly related to PR-T in 6 patients. Conclusions. In the DIAMOND study 
patient cohort, renal function, graft survival, and patient survival were similar between treatment arms at 5 y posttransplant.
(Transplantation Direct 2021;7: e722; doi: 10.1097/TXD.0000000000001166. Published online 9 July, 2021.)
ClinicalTrials.gov: NCT02057484.
All authors contributed to the interpretation of data and critical review of the 
article at all stages of its development. S.F., G.T., F.N., F.L., W.S., W.O.B., S.V.Z., 
H.I., O.O.R., J.K., and P.T. contributed to data acquisition. S.A., M.H., and N.U. 
contributed to the study design. G.K. contributed to the study design and data 
analysis.
S.A., M.H., and N.U. were employees of Astellas at the time of the study. G.K. is 
a consultant statistician working on behalf of Astellas, and he has also received 
support for travel from Astellas. All authors received nonfinancial support from 
Astellas during the conduct of the study.
This study was sponsored by Astellas Pharma Europe, Ltd. Medical writing and 
editorial support were funded by Astellas Pharma, Inc.
Researchers may request access to anonymized participant-level data, 
trial-level data and protocols from Astellas sponsored clinical trials at www.
clinicalstudydatarequest.com. For the Astellas criteria on data sharing see: 
https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-
Astellas.aspx.
Supplemental digital content (SDC) is available for this article. Direct URL 
citations appear in the printed text, and links to the digital files are provided in the 
HTML text of this article on the journal’s Web site (www.transplantationdirect.
com).
Correspondence: Pavel Trunečka, MD, PhD, Department of Hepatogastroe
nterology,  Transplant Centre, Institute for Clinical and Experimental Medicine, 
Vídeňská 1958/9, 140 21 Prague 4 - Krč, Czech Republic. (patr@ikem.cz).
2 Transplantation DIRECT   ■   2021 www.transplantationdirect.com
INTRODUCTION
Liver transplantation is a life-saving procedure that can 
restore patients with end-stage liver disease or acute liver 
failure to good health and normal activity.1,2 Data from the 
European Liver Transplant Registry (ELTR) indicate that the 
1-y patient survival rate after liver transplantation is 86% 
(2010–2014 data); however, long-term outcomes remain a 
challenge, with 5-y patient survival reported as 74%.3
Liver transplant recipients require lifelong, controlled expo-
sure to immunosuppressive therapy to prevent cellular and 
antibody-mediated graft rejection, while minimizing drug-
related toxicity.4 Tacrolimus is a calcineurin inhibitor (CNI) 
that is the cornerstone of immunosuppression in solid organ 
transplantation. The most commonly used immunosuppressive 
regimen in liver transplantation consists of tacrolimus in com-
bination with mycophenolate mofetil (MMF) and/or corticos-
teroids.5 Tacrolimus was originally marketed as a twice-daily, 
immediate-release formulation, but in 2007, a once-daily, pro-
longed-release formulation was marketed in many countries 
worldwide for use in stable liver transplant recipients or for 
administration to de novo patients.6
For liver transplant recipients, prolonged-release tacroli-
mus may offer several important clinical advantages over the 
traditional formulation. Tacrolimus has a narrow therapeutic 
index,7 and reducing intrapatient variability in exposure8-10 via 
improved delivery of tacrolimus and potentially better adher-
ence to the simplified once-daily regimen11,12 may improve 
long-term outcomes. In a retrospective analysis of data from 
the ELTR, patients who received prolonged-release tacrolimus 
following transplantation demonstrated a significantly higher 
rate of graft survival at 4 y posttransplant compared with 
those who received immediate-release tacrolimus (84% ver-
sus 79%, respectively). Patient survival at 4 y was also higher 
in the group receiving prolonged-release versus immediate-
release tacrolimus (85% versus 81%, respectively).13
One of the drawbacks of administering CNIs post-liver 
transplantation is considered to be the risk of renal impair-
ment,14,15 which is one of the main causes of poor long-term 
outcomes in liver transplant recipients.16 Strategies to mini-
mize the adverse renal effects of CNIs include decreasing ini-
tial exposure17-20 or delaying their introduction until 3–4 d 
posttransplantation.21 For example, in the ReSpECT study, 
a regimen with low-dose, delayed initiation of immediate-
release tacrolimus was associated with reduced renal func-
tion impairment at 52 wk compared with standard-dose, 
immediate-release tacrolimus-based treatment immediately 
posttransplant—without increased frequency of biopsy-
confirmed acute rejection (BCAR), graft loss, or death.21 
Furthermore, the phase 3b ADVAGRAF studied in combi-
nation with mycophenolate mofetil and basiliximab in liver 
transplantation (DIAMOND) trial evaluated renal function 
in de novo liver transplant patients receiving standard-dose, 
reduced-dose, or delayed initiation of prolonged-release 
tacrolimus. Patients receiving the reduced- and delayed-dose 
regimens also received basiliximab.22 The reduced initial dose 
regimen administered immediately posttransplant was asso-
ciated with significantly reduced renal function impairment 
and a significantly lower incidence of BCAR compared with 
the standard-dose regimen. The delayed tacrolimus regimen 
was also associated with significantly reduced renal func-
tion impairment compared with the standard-dose regimen, 
although BCAR incidence was comparable.
Findings from the DIAMOND trial suggest that delayed 
or reduced-dose prolonged-release tacrolimus regimens may 
improve renal outcomes compared with standard-dose regi-
mens. However, DIAMOND was a 6-mo study, and, therefore, 
it is unclear whether these tacrolimus minimization strategies 
in the early post-liver transplant period have an impact on 
long-term transplant outcomes.
Herein, we report 5-y prospective follow-up data from the 
DIAMOND patient cohort. The primary objective of this fol-
low-up study was to assess long-term graft survival in liver 
transplant recipients treated with regimens of standard-dose, 
reduced-dose, or delayed initiation of prolonged-release tac-
rolimus in the early posttransplant period. Secondary objec-
tives included assessment of long-term patient survival, renal 
function, and the incidence of acute rejection (AR) and BCAR. 
Graft survival in patients receiving prolonged-release tacroli-
mus for ≥30 d was also assessed, as was the safety of long-term 
treatment with prolonged-release tacrolimus.
MATERIALS AND METHODS
Study Design
Details of the DIAMOND study (ClinicalTrials.gov: 
NCT01011205) have been described previously.22 In brief, 
DIAMOND was a 24-wk, randomized, open-label, phase 3b 
study of de novo liver transplant patients receiving once-daily, 
prolonged-release tacrolimus (Advagraf, Astellas Pharma 
Europe BV, Netherlands)-based immunosuppression regi-
mens. Patients were not excluded if they had hepatocellular 
carcinoma. Eligible adult patients underwent primary ortho-
topic or partial liver transplantation. There were 3 rand-
omized treatment arms: Arm 1, prolonged-release tacrolimus 
(initial dose 0.2 mg/kg/d); Arm 2, prolonged-release tacroli-
mus (0.15–0.175 mg/kg/d) plus basiliximab; and Arm 3, pro-
longed-release tacrolimus (0.2 mg/kg/d delayed until d 5 post 
transplant) plus basiliximab. All patients additionally received 
MMF plus a single bolus of corticosteroids (no maintenance 
corticosteroids).
The present study (ClinicalTrials.gov: NCT02057484) was 
a 5-y, noninterventional, prospective follow-up of patients who 
received a liver transplant and were assigned to treatment with 
prolonged-release tacrolimus as participants in the DIAMOND 
study. Patients who provided informed consent (written or ver-
bal) were eligible to participate in the follow-up study.
The study was conducted in accordance with the Declaration 
of Helsinki, Good Clinical Practice, International Conference 
on Harmonisation guidelines, and applicable national laws 
and regulations. An independent ethics committee at each 
center granted approval of the follow-up study before initia-
tion. Patients could withdraw from the study for any reason, 
at any time, without giving a reason for doing so and with-
out penalty or prejudice. Patients were discontinued from the 
study if they died, were lost to follow-up, or withdrew consent.
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Treatment
Patients were grouped according to their original rand-
omized treatment arm in the DIAMOND study. Patients were 
maintained on their usual immunosuppressive regimen accord-
ing to standard clinical practice.
Assessments
The follow-up period included 6 study visits. Patients had a 
baseline visit (visit 1) on their DIAMOND end of study (EOS) 
date, whereas those who had already completed DIAMOND 
had visit 1 at their next scheduled appointment (up to d 181 
posttransplant). Subsequent visits were scheduled annually 
starting 1 y (± 4 mo) posttransplant.
Endpoints
The primary endpoint was overall graft survival, defined as 
time from transplantation to graft loss (retransplantation or 
death). Secondary endpoints included: overall patient survival, 
estimated glomerular filtration rate (eGFR; based on both the 
4-variable Modification of Diet in Renal Disease [MDRD4] 
formula23 and the Chronic Kidney Disease Epidemiology 
Collaboration formula24) and AR and BCAR episodes (sever-
ity assessed by Banff classification25-27).
Tacrolimus dose and duration of treatment, and concomi-
tant or other immunosuppressive therapy use were reported. 
Concomitant immunosuppressive medications included all 
medications administered to the patient during the follow-up 
study that may or may not have been administered concomi-
tantly with tacrolimus. Adverse events (AEs) and adverse drug 
reactions (ADRs) were recorded throughout the follow-up 
period and were classified by system organ class and preferred 
term according to the Medical Dictionary for Regulatory 
Activities (version 16.1). An ADR was defined as a response 
to prolonged-release tacrolimus that was noxious and 
unintended. Response in this context implied that a causal 
relationship between prolonged-release tacrolimus and the AE 
was at least a reasonable possibility.
Statistical Analyses
Analysis Sets
The enrolled patient set (EPS) comprised all patients who 
enrolled in the DIAMOND study, had a liver transplant, and 
received at least 1 dose of prolonged-release tacrolimus. The 
follow-up patient set (FPS) comprised patients in the EPS who 
consented to the follow-up study or who died during DIAMOND 
or before the start of the follow-up study before they could 
give consent. Patients who were lost to follow-up between the 
DIAMOND EOS date and the start of the long-term follow-up 
study, or who did not provide informed consent for the long-term 
follow-up study, were included in the analysis up to the date when 
they discontinued or completed DIAMOND.
Descriptive Statistics
Data for patient demographics and clinical characteristics, 
tacrolimus dosing and exposure, use of other immuno sup-
pressants, renal function, and safety and tolerability are pre-
sented using mean with SD or numbers and percentages, as 
appropriate.
Analysis of Time-to-Event Endpoints
The Kaplan-Meier method was used to analyze overall 
graft survival (the primary endpoint), as well as overall patient 
survival, AR, and BCAR. Patients without graft loss were cen-
sored at the follow-up EOS date or last evaluation date. Post 
hoc analyses of death-censored graft survival (graft survival 
censored for death with a functioning graft), graft survival 
and death-censored graft survival in patients who remained 
on tacrolimus for ≥30 d after transplantation, and graft and 
patient survival while receiving prolonged-release tacrolimus 
were also performed. Graft survival estimates at 1, 2, 3, 4, and 
5 y posttransplant were calculated, with corresponding 2-sided 
95% confidence intervals (CIs) using the normal approxima-
tion method. Kaplan-Meier analyses were performed on the 
EPS. Time-to-event endpoints were also analyzed using a Cox 
proportional hazards model, adjusted for treatment arm (Arm 
1 versus Arm 3; Arm 2 versus Arm 3), donor age (≥50 y versus 
<50 y), sex, donor type (living versus deceased), and hepatitis 
C virus (HCV) status.
RESULTS
Patient Characteristics
A total of 856 patients who had previously enrolled in the 
DIAMOND study were included in the EPS. The FPS (patients 
who consented to the follow-up study or died before they could 
give consent) included 617 patients, of whom 443 (71.8%) 
completed the long-term follow-up study (Figure 1); 4 patients 
died after enrollment into the follow-up study. In the FPS, the 
mean (SD) age at baseline was 54.3 y (9.8 y), and 71.8% of 
patients were male (Table 1). Baseline demographics and clini-
cal characteristics were similar in the 3 treatment arms (Arm 1, 
n = 196; Arm 2, n = 212; and Arm 3, n = 209).
Tacrolimus Dosing and Exposure
The overall mean (SD) daily dose of prolonged-release tac-
rolimus decreased from 0.063 mg/kg (0.04 mg/kg) at 1-y post 
transplant to 0.039 mg/kg (0.03 mg/kg) at 5 y posttransplant. 
Mean daily doses of prolonged-release tacrolimus were similar 
in the 3 treatment arms at all time points (Table 2). The overall 
mean (SD) duration of prolonged-release tacrolimus from trans-
plantation was 870.1 d (817.5 d). The mean duration of pro-
longed-release tacrolimus was higher in Arm 3 (940.7 d) than in 
Arms 1 (840.4 d) or 2 (831.4 d), suggesting that a lower propor-
tion of patients in Arm 3 than in the other 2 arms discontinued 
treatment with prolonged-release tacrolimus. Of 856 patients in 
the EPS, 381 remained on prolonged-release tacrolimus at 1 y, 
355 at 3 y, and 134 at 5 y. After the first year of treatment, few 
patients discontinued prolonged-release tacrolimus because of 
graft loss or death.
In accordance with the decreasing tacrolimus daily dose 
over time, overall mean (SD) tacrolimus trough levels were 
7.4 ng/mL (2.8 ng/mL) at 1 y and 5.2 ng/mL (2.1 ng/mL) at 5 y 
posttransplant. Mean tacrolimus trough levels were similar in 
the 3 treatment arms at all time points (Table 3).
Concomitant and Other Immunosuppressants
Almost two-thirds of patients (64.2%) took at least 1 con-
comitant immunosuppressive medication during the follow-up 
study (Table 4). The most common concomitant immunosup-
pressant in the FPS was MMF (57.4%). Other immunosup-
pressive medications taken by >5% of patients in any treatment 
arm in the FPS were systemic corticosteroids (14.6%), the 
mammalian target of rapamycin inhibitors, everolimus or 
sirolimus (12.2%), and ciclosporin (5.2%; not administered 
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with tacrolimus). Concomitant or other immunosuppressive 
medication use was similar between treatment arms, except for 
everolimus, which was taken less frequently in Arm 2 (4.7%) 
than in Arm 1 (10.2%) or Arm 3 (10.5%).
Primary Efficacy Endpoint: Graft Survival
At 1-y posttransplant, overall graft survival was 84.6% (95% 
CI, 82.0%-87.1%), decreasing to 73.5% (95% CI, 70.2%-
76.8%) at 5 y posttransplant (Figure 2A). Graft survival rates 
FIGURE 1. Patient disposition and analysis sets. aPatients who died during DIAMOND or between DIAMOND and the start of the follow-up study 
were included in the FPS but were not considered to have completed the follow-up study. DIAMOND, ADVAGRAF studied in combination with 
mycophenolate mofetil and basiliximab in liver transplantation; EPS, enrolled patient set; FPS, follow-up patient set.
TABLE 1.
Baseline demographics and clinical characteristics (FPS)
Parameter Arm 1a (n = 196) Arm 2b (n = 212) Arm 3c (n = 209) Total (N = 617)
Age, y, mean (SD) 54.4 (9.1) 54.0 (10.1) 54.4 (10.0) 54.3 (9.8)
Male sex, n (%) 142 (72.4) 155 (73.1) 146 (69.9) 443 (71.8)
Ethnicity, White, n (%) 189 (96.4) 200 (94.3) 201 (96.2) 590 (95.6)
Body mass index, kg/m2, mean (SD) 26.5 (4.8) 26.9 (5.5) 26.4 (4.4) 26.6 (4.9)
eGFR (MDRD4), mL/min/1.73 m2, mean (SD)d 66.9 (26.7) 73.55 (34.1) 68.5 (28.9) 69.7 (30.2)
Last measured tacrolimus trough level (ng/mL), mean (SD)d 8.1 (3.9) 8.5 (4.6) 7.8 (4.0) 8.1 (4.2)
Patients with graft loss before start of follow-up study, n (%) 36 (18.4) 34 (16.0) 31 (14.8) 101 (16.4)
Recipient viral status, n (%)
 CMV positive 130 (66.3) 150 (70.8) 140 (67.0) 420 (68.1)
 HBV negative 170 (86.7) 180 (84.9) 185 (88.5) 535 (86.7)
 HCV negative 134 (68.4) 154 (72.6) 149 (71.3) 437 (70.8)
 HIV negative 195 (99.5) 212 (100.0) 206 (98.6) 613 (99.4)
Donor age, y, mean (SD) 51.8 (17.5) 51.3 (18.0) 51.3 (17.9) 51.5 (17.8)
Organ donor type, n (%)     
 Deceased 190 (96.9) 207 (97.6) 202 (96.7) 599 (97.1)
 Living nonrelated 2 (1.0) 1 (0.5) 2 (1.0) 5 (0.8)
 Living related 4 (2.0) 4 (1.9) 5 (2.4) 13 (2.1)
aArm 1: prolonged-release tacrolimus (initial dose 0.2 mg/kg/d) + MMF.
bArm 2: prolonged-release tacrolimus (initial dose 0.15–0.175 mg/kg/d) + MMF + basiliximab.
cArm 3: prolonged-release tacrolimus (initial dose 0.2 mg/kg/d delayed until day 5) + MMF + basiliximab.
dMeasured at DIAMOND EOS (d 168 ± 42 d).
CMV, cytomegalovirus; DIAMOND, ADVAGRAF studied in combination with mycophenolate mofetil and basiliximab in liver transplantation; eGFR, estimated glomerular filtration rate; EOS, end of study; 
FPS, follow-up patient set; HBV, hepatitis B virus; HCV, hepatitis C virus; MDRD4, 4-variable Modification of Diet in Renal Disease; MMF, mycophenolate mofetil.
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at 5 y for treatment Arms 1, 2, and 3 were comparable: 74.7% 
(95% CI, 68.9%-80.4%), 71.5% (95% CI, 65.5%-77.4%), 
and 74.5% (95% CI, 68.8%-80.2%), respectively (Figure 2B). 
A post hoc analysis of overall death-censored graft survival 
showed similar results to the primary analysis: 85.9% (95% 
CI, 83.5%-88.4%) at 1 y and 74.7% (95% CI, 71.4%-78.0%) 
at 5 y posttransplant (Figure S1, SDC, http://links.lww.com/
TXD/A331).
TABLE 2.
Total daily dose of prolonged-release tacrolimus over time (FPS)
Visit Time point Arm 1a (n = 196) Arm 2b (n = 212) Arm 3c (n = 209) Total (N = 617)
1 DIAMOND EOS (d 181) 0.09 (0.06) 0.09 (0.07) 0.09 (0.06) 0.09 (0.06)
 N 190 207 192 589
2 1 y (d 182–547) 0.06 (0.03) 0.06 (0.04) 0.07 (0.05) 0.06 (0.04)
 n 122 125 132 379
3 2 y (d 548–913) 0.04 (0.03) 0.05 (0.03) 0.05 (0.04) 0.05 (0.03)
 n 118 124 125 367
4 3 y (d 914–1278) 0.04 (0.02) 0.04 (0.03) 0.05 (0.03) 0.04 (0.03)
 n 110 117 120 347
5 4 y (d 1279–1643) 0.04 (0.02) 0.04 (0.03) 0.04 (0.03) 0.04 (0.03)
 n 110 115 119 344
6/EOS 5 y (d 1644–2009) 0.04 (0.02) 0.04 (0.03) 0.04 (0.03) 0.04 (0.03)
 n 110 113 119 342
aArm 1: prolonged-release tacrolimus (initial dose 0.2 mg/kg/d) + MMF.
bArm 2: prolonged-release tacrolimus (initial dose 0.15–0.175 mg/kg/d) + MMF + basiliximab.
cArm 3: prolonged-release tacrolimus (initial dose 0.2 mg/kg/d delayed until d 5) + MMF + basiliximab.
Data are mean (SD) mg/kg/d.
DIAMOND, ADVAGRAF studied in combination with mycophenolate mofetil and basiliximab in liver transplantation; EOS, end of study; FPS, follow-up patient set; MMF, mycophenolate mofetil.
TABLE 3.
Whole-blood trough levels of tacrolimus over time (FPS)
Visit Time point Arm 1a (n = 196) Arm 2b (n = 212) Arm 3c (n = 209) Total (N = 617)
1 DIAMOND EOS (d 181) 8.2 (4.0) 8.5 (4.6) 7.9 (4.0) 8.2 (4.2)
 n 185 205 191 581
2 1 y (d 182–547) 7.4 (3.0) 7.3 (3.0) 7.6 (2.6) 7.4 (2.8)
 n 133 140 135 408
3 2 y (d 548–913) 6.7 (2.6) 6.2 (2.4) 6.8 (3.2) 6.6 (2.8)
 n 126 130 127 383
4 3 y (d 914–1278) 5.4 (1.8) 5.7 (2.7) 5.7 (2.3) 5.6 (2.3)
 n 120 124 125 369
5 4 y (d 1279–1643) 5.1 (1.8) 5.4 (2.7) 6.3 (5.3) 5.6 (3.7)
 n 116 122 127 365
6/EOS 5 y (d 1644–2009) 5.4 (1.9) 4.9 (2.0) 5.4 (2.4) 5.2 (2.1)
 N 117 122 121 360
aArm 1: prolonged-release tacrolimus (initial dose 0.2 mg/kg/d) + MMF.
bArm 2: prolonged-release tacrolimus (initial dose 0.15–0.175 mg/kg/d) + MMF + basiliximab.
cArm 3: prolonged-release tacrolimus (initial dose 0.2 mg/kg/d delayed until d 5) + MMF + basiliximab.
Data are mean (SD) ng/mL.
DIAMOND, ADVAGRAF studied in combination with mycophenolate mofetil and basiliximab in liver transplantation; EOS, end of study; FPS, follow-up patient set; MMF, mycophenolate mofetil.
TABLE 4.
Concomitant or other immunosuppressive medications taken by ≥5% of patients in 1 of the treatment arms (FPS)
Medication Arm 1a (n = 196) Arm 2b (n = 212) Arm 3c (n = 209) Total (N = 617)
≥1 concomitant immunosuppressant 129 (65.8) 130 (61.3) 137 (65.6) 396 (64.2)
Mycophenolate mofetil 115 (58.7) 122 (57.5) 117 (56.0) 354 (57.4)
Systemic corticosteroid 33 (16.8) 24 (11.3) 33 (15.8) 90 (14.6)
Everolimus 20 (10.2) 10 (4.7) 22 (10.5) 52 (8.4)
Ciclosporin 10 (5.1) 13 (6.1) 9 (4.3) 32 (5.2)
Sirolimus 10 (5.1) 8 (3.8) 5 (2.4) 23 (3.7)
aArm 1: prolonged-release tacrolimus (initial dose 0.2 mg/kg/d) + MMF.
bArm 2: prolonged-release tacrolimus (initial dose 0.15–0.175 mg/kg/d) + MMF + basiliximab.
cArm 3: prolonged-release tacrolimus (initial dose 0.2 mg/kg/d delayed until day 5) + MMF + basiliximab.
Data are n (%).
DIAMOND, ADVAGRAF studied in combination with mycophenolate mofetil and basiliximab in liver transplantation; FPS, follow-up patient set; MMF, mycophenolate mofetil.
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At 5 y posttransplant, graft survival and death-censored 
graft survival in patients who remained on prolonged-release 
tacrolimus for ≥30 d were 79.1% (95% CI, 75.8%-82.4%) 
and 79.3% (95% CI, 76.0%-82.6%), respectively (Figure S1, 
SDC, http://links.lww.com/TXD/A331). Graft survival over 5 
y in patients who remained on prolonged-release tacrolimus 
was 87.3% (95% CI, 84.8%-89.7%) (Figure S1, SDC, http://
links.lww.com/TXD/A331).
Cox proportional hazards model analysis of overall graft 
survival (Table 5) showed that patients with positive HCV sta-
tus at baseline had a higher hazard of graft loss than patients 
with negative HCV status: hazard ratio (HR) 1.93 (95% CI, 
1.44-2.58). There were no differences in the risk of graft loss 
between treatment arms, donor age, donor type, or sex.
Graft Survival by 12-mo eGFR
Kaplan-Meier estimated graft survival at 5 y was 
generally comparable in patients with 12-mo eGFR 
30–60 mL/min/1.73 m2 or ≥60 mL/min/1.73 m2, irrespective of 
treatment arm (range between 91.0% and 98.1%). In Arms 
1 and 2, posttransplant eGFR <30 mL/min/1.73 m2 at 12 mo 
was associated with numerically worse 5-y graft survival rates 
(88.9% and 88.2%, respectively) compared with eGFR 30–
60 or ≥60 mL/min/1.73 m2. No patients in Arm 3 with eGFR 
<30 mL/min/1.73 m2 lost their graft. However, the findings in 
patients with eGFR <30 mL/min/1.73 m2 should be interpreted 
with caution because of small patient numbers (n = 18, n = 17, 
and n = 14 in Arms 1–3, respectively).
Secondary Efficacy Endpoints
Patient Survival
At 1 y posttransplant, overall patient survival was 86.6% 
(95% CI, 84.1%-89.0%), decreasing to 76.3% (95% CI, 
73.1%-79.6%) at 5 y posttransplant (Figure 2C). Patient sur-
vival rates for treatment Arms 1, 2, and 3 were similar at 5 
y: 78.6% (95% CI, 73.2%-84.1%), 73.8% (95% CI, 68.1%-
79.6%), and 76.7% (95% CI, 71.2%-82.3%), respectively 
(Figure 2D). In a post hoc analysis of survival in patients who 
remained on prolonged-release tacrolimus, survival rate was 
90.6% (95% CI, 88.5%-92.8%) (Figure S2, SDC, http://links.
lww.com/TXD/A331).
Cox proportional hazards model analysis of overall patient 
survival (Table 5) showed that patients with a positive baseline 
A B
C D
FIGURE 2. Kaplan-Meier plots of graft and patient survival (EPS). A, Overall graft survival. B, Graft survival by treatment arm. C, Overall patient survival. 
D, Patient survival by treatment arm. Arm 1: prolonged-release tacrolimus (initial dose 0.2 mg/kg/d) + MMF; Arm 2: prolonged-release tacrolimus 
(initial dose 0.15–0.175 mg/kg/d) + MMF + basiliximab; and Arm 3: prolonged-release tacrolimus (initial dose 0.2 mg/kg/d delayed until d 5 post 
transplant) + MMF + basiliximab. Time to graft loss was defined as the time from transplantation to graft loss, including graft loss events that occurred in 
DIAMOND. Graft loss was defined as retransplantation or death. Patients were censored at last evaluation if no event. DIAMOND, ADVAGRAF studied 
in combination with mycophenolate mofetil and basiliximab in liver transplantation; EPS, enrolled patient set; MMF, mycophenolate mofetil.
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HCV status had a higher hazard of death than patients with a 
negative baseline HCV status (HR, 2.00; 95% CI, 1.47-2.74). 
Male patients had a higher risk of death than female patients 
(HR, 1.59; 95% CI, 1.01-2.32). There was no difference in the 
risk of death between treatment arms, donor age, or donor type.
Overall Survival by Baseline eGFR
Kaplan-Meier estimated 5-y overall survival was numeri-
cally lower in patients with baseline eGFR <30 mL/min/1.73 m2 
than in patients with baseline eGFR ≥60 mL/min/1.73 m2, 
irrespective of treatment arm (EPS). Overall survival at 5 y 
in patients with eGFR <30 mL/min/1.73 m2 versus ≥60 mL/
min/1.73 m2 was 56.5% (95% CI, 32.2%-80.8%) versus 
85.3% (95% CI, 79.1%-91.6%) in Arm 1, 48.4% (95% CI, 
23.1%-73.7%) versus 77.0% (95% CI, 70.0%-83.9%) in 
Arm 2, and 16.7% (95% CI, 0.0%-43.3%) versus 82.1% 
(95% CI, 75.5%-88.8%) in Arm 3.
Renal Function
Mean (SD) overall eGFR (MDRD4) was similar at the 
DIAMOND EOS and at 5 y posttransplant: 62.1 mL/
min/1.73 m2 (37.6 mL/min/1.73 m2) and 61.5 mL/min/1.73 m2 
(30.4 mL/min/1.73 m2), respectively (Table 6). Although mean 
eGFR (MDRD4) was numerically lower in Arm 1 than in 
Arms 2 and 3 at the DIAMOND EOS, eGFR was comparable 
between arms by year 1, and there were no obvious differences 
between the 3 treatment arms at the end of the observation 
period. Similar results were observed for calculation of eGFR 
using the Chronic Kidney Disease Epidemiology Collaboration 
method (Table  6). Mean (SD) eGFR (MDRD4) for patients 
who remained on prolonged-release tacrolimus was similar 
at the DIAMOND EOS and at 5 y posttransplant (62.3 mL/
min/1.73 m2 [35.6 mL/min/1.73 m2] and 64.5 mL/min/1.73 m2 
[29.9 mL/min/1.73 m2], respectively).
Acute Rejection
Most AR episodes occurred in the first 6 mo posttrans-
plant (Figure  3A and B). The overall AR-free survival rate 
was 82.2% at 6 mo, and 78.7% at 5 y posttransplant. At 6 
mo posttransplant, a greater proportion of patients were 
AR-free in Arm 2 (86.8%) versus Arm 1 (80.0%) or Arm 3 
(79.7%). At 5 y posttransplant, the AR-free survival rate 
remained higher in Arm 2 (83.5%) versus Arm 1 (76.6%) or 
Arm 3 (75.8%).
Biopsy-confirmed Acute Rejection
As seen with AR, most BCAR episodes were reported in 
the first 6 mo posttransplant (Figure  3C and D). The over-
all BCAR-free survival rate was 84.8% at 6 mo, and 81.9% 
at 5 y posttransplant. BCAR-free survival at 6 mo was 
higher in Arm 2 (89.0%) than in Arm 1 (82.2%) or Arm 3 
(83.1%), and remained higher at 5 y posttransplant (86.3%) 
compared with Arm 1 (79.5%) and Arm 3 (79.9%). In most 
patients, BCAR was classified as mild or moderate; severe 
BCAR was experienced by 10 patients (1.2%) at baseline (visit 
1) and 1 patient (0.1%) at 2 y posttransplant.
Safety and Tolerability
In the FPS, 1 or more AEs were experienced by 93 patients 
(15.1%) (Table  7). The most common AEs were asthenia 
(1.0%) and incisional hernia (1.0%). No patients had AEs 
leading to discontinuation of tacrolimus. In total, 18 patients 
(2.9%) had at least 1 ADR, of whom 6 (1.0%) had at least 1 
ADR classified as “probably tacrolimus-related,” as assessed 
by the investigator. The most common probably tacrolimus-
related ADR was renal failure, which was the only ADR that 
occurred in >1 patient (n = 2). No patients experienced ADRs 
leading to death. A total of 22 patients developed diabetes, 
including 21 patients between the end of the DIAMOND 
study and provision of informed consent for the follow-up 
study and 1 patient during the follow-up study.
DISCUSSION
In this 5-y, prospective follow-up of a large patient 
cohort (n = 856) from the 24-wk DIAMOND study, we 
evaluated long-term graft survival in liver transplant recipi-
ents treated with prolonged-release tacrolimus-based 
immunosuppression. Overall, graft and patient survival rates 
at 5 y posttransplant were 73.5% and 76.3%, respectively, 
and were similar in the 3 treatment arms. The overall death-
censored graft survival rate was 74.7%. Graft survival and 
death-censored graft survival rates were 79.1% and 79.3%, 
respectively, for patients who remained on prolonged-release 
tacrolimus for ≥30 d. Both graft and patient survival were 
numerically highest in the group of patients who remained on 
prolonged-release tacrolimus (87.3% and 90.6%, respectively, 
at 5 y). Graft survival rates for patients who remained on 
prolonged-release tacrolimus for ≥30 d were comparable with 
the 4-y graft survival rates in patients receiving prolonged-
release tacrolimus following liver transplantation reported by 
the ELTR (79% and 84%, respectively).13 In both instances, 
patients who received prolonged-release tacrolimus for <1 mo 
were excluded. In our study, graft survival rates were numeri-
cally higher in the cohort receiving prolonged-release tacroli-
mus for ≥30 d than in the overall cohort. This highlights the 
impact of graft loss resulting from causes other than failed 
immunosuppression that can occur within the first month after 
liver transplantation.
Cox proportional hazards analysis showed that patients with 
a positive baseline HCV status had a higher risk of graft loss and 
death than patients with a negative HCV status. This finding is 
well known and consistent with historic data showing that a 
positive HCV status is a major risk factor for reduced long-term 
graft and patient survival.28 However, HCV recurrence of the 
transplanted liver is no longer a major clinical concern, because 
of the inception of direct-acting antiviral agents. Our analysis 
TABLE 5.
Cox proportional hazards model analysis of overall graft 
and patient survival (EPS)
Model parameter Subgroups
Hazard ratio (95% CI)
Graft survival Patient survival
HCV status Positive vs negative 1.93 (1.44-2.58) 2.01 (1.47-2.74)
Sex Male vs female 1.37 (0.98-1.92) 1.59 (1.10-2.32)
Donor age ≥50 y vs <50 y 1.33 (0.99-1.79) 1.22 (0.89-1.67)
Donor type Living vs deceased 1.22 (0.50-2.98) 0.78 (0.25-2.47)
Treatment arm Arm 1a vs Arm 3b 1.01 (0.71-1.45) 0.93 (0.63-1.36)
 Arm 2c vs Arm 3b 1.14 (0.81-1.62) 1.16 (0.81-1.67)
aArm 1: prolonged-release tacrolimus (initial dose 0.2 mg/kg/d) + MMF.
bArm 3: prolonged-release tacrolimus (initial dose 0.2 mg/kg/d delayed until d 5) + MMF + basi-
liximab.
cArm 2: prolonged-release tacrolimus (initial dose 0.15–0.175 mg/kg/d) + MMF + basiliximab.
CI, confidence interval; EPS, enrolled patient set; HCV, hepatitis C virus; MMF, mycophenolate 
mofetil.
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also showed that male patients appear to have a higher risk of 
death than female patients. This difference only emerged dur-
ing the long-term follow-up period as, in the original 24-wk 
DIAMOND study, there were no significant differences in mor-
tality between male and female patients.22 Although the findings 
from our follow-up study are consistent with long-term survival 
data from the ELTR,13 other studies report a higher mortal-
ity rate in female patients compared with male patients,29,30 or 
no difference between sexes in liver graft survival.31 Given the 
inconsistency in survival between sexes, results from the Cox 
analysis in our study should be interpreted with caution.
A decline in renal function is one of the main causes of 
poor long-term outcomes in liver transplant recipients.16 Data 
from the US National Institute of Diabetes and Digestive and 
Kidney Diseases liver transplantation database showed that 
the effect of renal failure on patient mortality increases over 
time (HR was 2.4 at 1 y posttransplant, increasing to 7.5 at 
5 y).16 In the present study, renal function as measured by 
mean eGFR (MDRD4) remained stable from 1 y (63.6 mL/
min/1.73 m2) to 5 y (61.5 mL/min/1.73 m2) posttransplant, in 
line with the high rates of patient survival observed. Although 
there was a gradual decline in mean eGFR over 5 y in Arm 2 
(from 66.0 mL/min/1.73 m2 at DIAMOND EOS to 62.5 mL/
min/1.73 m2 at 5 y) and there was a numeric improvement 
in Arm 1 (from 57.6 mL/min/1.73 m2 at DIAMOND EOS 
to 62.3 mL/min/1.73 m2 at 5 y), the clinical significance of 
these findings is unclear. After the initial tacrolimus dose, as 
per the randomized regimen, investigators were allowed to 
adjust the dose to maintain target tacrolimus trough levels, 
and the patients were observed in the real world after the 
first 6 mo of treatment. Therefore, as the initial tacrolimus 
dosing regimens were not maintained long-term and tacroli-
mus trough levels were subsequently managed by the sites 
as per the drug label, this may account for the generally 
comparable tacrolimus trough levels during follow-up and 
similar 5-y renal function between study arms. Overall, the 
data suggest that the immunosuppressive regimens utilized 
in the original DIAMOND study, and subsequent long-term 
prolonged-release tacrolimus use, do not negatively affect 
long-term renal function, which is encouraging for clinical 
practice.
AR after liver transplantation is associated with a signifi-
cantly increased risk of graft failure, all-cause mortality, and 
graft failure-related death.32 In this study, AR- and BCAR-free 
survival rates were high at 5 y posttransplant (78.7% and 
81.9%, respectively), with most episodes occurring within the 
first 6 mo posttransplant. We found that AR- and BCAR-free 
survival rates at 6 mo in Arm 2 (prolonged-release tacrolimus 
0.15–0.175 mg/kg/d immediately posttransplant plus basilixi-
mab) were numerically higher than those in Arm 1 (prolonged-
release tacrolimus 0.2 mg/kg/d immediately posttransplant) 
or Arm 3 (prolonged-release tacrolimus 0.2 mg/kg/d delayed 
until day 5 posttransplant plus basiliximab), and the differ-
ence was maintained through to 5 y posttransplantation. It 
should be noted that Arms 2 and 3 received induction ther-
apy with basiliximab, which might have impacted outcomes 
TABLE 6.
Renal function (eGFR) over time by MDRD4 and CKD-EPI (FPS)
Visit Time point Arm 1a (n = 196) Arm 2b (n = 212) Arm 3c (n = 209) Total (N = 617)
1 DIAMOND EOS (d 181)
 n 195 212 209 616
 MDRD4 57.6 (36.2) 66.0 (40.8) 62.5 (35.2) 62.1 (37.6)
 CKD-EPI 56.7 (34.0) 63.6 (34.9) 61.6 (32.9) 60.7 (34.0)
2 1 y (d 182–547)
 n 146 150 151 447
 MDRD4 62.5 (32.7) 65.6 (30.9) 62.8 (28.8) 63.6 (30.8)
 CKD-EPI 62.1 (31.0) 65.6 (30.3) 63.2 (29.0) 63.6 (30.1)
3 2 y (d 548–913)
 n 145 145 147 437
 MDRD4 63.9 (32.2) 63.7 (29.4) 61.3 (28.0) 63.0 (29.9)
 CKD-EPI 63.5 (32.2) 63.7 (28.8) 62.1 (28.7) 63.1 (29.2)
4 3 y (d 914–1278)
 n 145 142 147 434
 MDRD4 63.3 (32.8) 62.0 (29.2) 59.6 (27.8) 61.6 (30.0)
 CKD-EPI 62.4 (30.2) 61.9 (28.8) 60.0 (28.5) 61.5 (29.1)
5 4 y (d 1279–1643)
 n 141 146 145 432
 MDRD4 61.9 (31.7) 62.4 (29.6) 61.9 (32.1) 62.1 (31.1)
 CKD-EPI 61.3 (30.4) 61.9 (28.9) 60.9 (29.5) 61.4 (29.5)
6/EOS 5 y (d 1644–2009)
 n 139 145 145 429
 MDRD4 62.3 (32.8) 62.5 (30.0) 59.8 (28.5) 61.5 (30.4)
 CKD-EPI 61.1 (29.9) 61.6 (28.7) 59.7 (28.5) 60.8 (29.0)
aArm 1: prolonged-release tacrolimus (initial dose 0.2 mg/kg/d) + MMF.
bArm 2: prolonged-release tacrolimus (initial dose 0.15–0.175 mg/kg/d) + MMF + basiliximab.
cArm 3: prolonged-release tacrolimus (initial dose 0.2 mg/kg/d delayed until d 5) + MMF + basiliximab.
Data are mean (SD) mL/min/1.73 m2.
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DIAMOND, ADVAGRAF studied in combination with mycophenolate mofetil and basiliximab in liver transplantation; eGFR, estimated 
glomerular filtration rate; EOS, end of study; FPS, follow-up patient set; MDRD4, 4-variable Modification of Diet in Renal Disease; MMF, mycophenolate mofetil.
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in the immediate posttransplant period. However, despite the 
link between AR and rates of graft and patient survival,32 
the higher rate of AR-free survival in Arm 2 compared with 
Arms 1 and 3 did not translate into improved rates of graft or 
patient survival in Arm 2. Whether this might be linked with 
the gradual decline in renal function or the lower tacrolimus 
trough levels at 5 y (4.9 ng/mL) observed in Arm 2 versus Arms 
1 and 3 is unclear.
Over the 5-y follow-up period, tacrolimus daily dose 
and trough levels decreased. At the end of the original 
DIAMOND study and during long-term follow-up, the 
mean tacrolimus daily dose and trough levels were similar 
between arms. This might be expected as the recommended 
tacrolimus trough levels were the same in all 3 treatment 
arms, and tacrolimus dose was titrated according to trough 
levels. During follow-up, approximately 35% of patients 
received monotherapy with prolonged-release tacrolimus. 
Furthermore, while all patients received MMF at the start 
of the DIAMOND study, ~40% of patients stopped MMF 
at some stage during DIAMOND or the follow-up study. 
The first 6 mo of the study were protocol-driven, and tac-
rolimus monotherapy was not permitted. During follow-up, 
patients were treated according to standard clinical practice, 
individual patient preference and medical need (eg, to treat a 
concomitant disease), which may have enabled cessation of 
MMF and subsequent monotherapy with prolonged-release 
tacrolimus.
Overall, the safety profile of the patients in the follow-up 
study was consistent with those of the primary DIAMOND 
study,22 and no new safety signals were detected. A small 
proportion of patients (1.0%) had ADRs that were con-
sidered probably tacrolimus-related during this follow-up 
study. In contrast to the observed high incidence of dia-
betes in the ReSpECT study (39%–48%),21 only 3.6% of 
patients in the FPS developed diabetes. The low incidence 
of diabetes during the follow-up study was probably related 
to the low proportion of patients (15%) taking systemic 
corticosteroids.33
The present study has several limitations. Firstly, this 
study was not powered to statistically compare treatment 
arms. Furthermore, the open-label design of both the rand-
omized phase and the long-term follow-up study means that 
results from both periods were susceptible to bias, includ-
ing selection bias regarding enrollment into the follow-up 
A B
C D
FIGURE 3. Kaplan-Meier plots of first episode of AR and BCAR (EPS). A, Overall AR-free survival. B, AR-free survival by treatment arm. C, 
Overall BCAR-free survival. D, BCAR-free survival by treatment arm. Arm 1: prolonged-release tacrolimus (initial dose 0.2 mg/kg/d) + MMF; Arm 
2: prolonged-release tacrolimus (initial dose 0.15–0.175 mg/kg/d) + MMF + basiliximab; and Arm 3: prolonged-release tacrolimus (initial dose 
0.2 mg/kg/d delayed until d 5 posttransplant) + MMF + basiliximab. AR, acute rejection; BCAR, biopsy-confirmed acute rejection; EPS, enrolled 
patient set; MMF, mycophenolate mofetil.
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study. Many patients with a functioning graft at the end 
of the initial DIAMOND trial did not enter the long-term 
follow-up study. Some sites (including those in Norway and 
Turkey) from the initial DIAMOND study did not partici-
pate because they lacked the resources, their patients did 
not respond to requests to participate, or they were not 
approached for logistical reasons. One site was not included 
because its ethics committee considered the study design 
interventional.
An additional limitation is that key factors associated with 
long-term graft survival in liver transplant recipients, including 
the development of de novo donor-specific antibodies34-36 and 
adherence to medication11,12 were not assessed here. Future 
studies that evaluate these factors are warranted. Additionally, 
as this was an observational study, factors associated with 
local clinical practice could have impacted the proportion of 
patients discontinuing treatment with prolonged-release tac-
rolimus—and these factors were not assessed.
CONCLUSIONS
In this long-term follow-up of a large cohort of patients who 
had previously enrolled in the DIAMOND study, renal func-
tion, graft survival, and patient survival were similar between 
treatment arms at 5 y posttransplant. Renal function remained 
generally stable through 5 y posttransplantation, and rates of 
AR- and BCAR-free survival were high, with most episodes 
reported during the first 6 mo posttransplant. The safety and 
tolerability profile was consistent with the DIAMOND study, 
and no new safety signals were reported over 5 y.
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